---
schema_version: "secwatch.filing_event.v1"
accession: "0001826466-24-000050"
form_type: "8-K"
ticker: "NIKA"
cik: "0001145604"
company_name: "NIKA PHARMACEUTICALS, INC"
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:45:06.133102+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Nika Pharma acquires 40% of Nika Europe, now owns 80%; buys 4 technologies for $24,683

## Summary
- Merger with Nika BioTechnology gave Nika Pharma an additional 40% stake in Nika Europe Ltd, bringing total to 80%.
- Nika Europe Ltd acquired three generic drug technologies and one dietary supplement technology from AIPFPCB.
- Purchase price was 45,000 BGN (~$24,683), paid by officer Dimitar Savov, who is also general manager of Nika Europe.
- Acquired drug technologies: Menthyl Valerate 0.06g, Metamizole Sodium 500mg, Vinpocetine 10mg; supplement: Tribulus Terrestris extract 250mg.

## SEC filing metadata
- accession: 0001826466-24-000050
- form_type: 8-K
- ticker: NIKA
- cik: 0001145604
- company_name: NIKA PHARMACEUTICALS, INC
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145604/000182646624000050/0001826466-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145604/000182646624000050/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826466-24-000050
- JSON: https://secwatch.observer/filing/0001826466-24-000050.json
- Plain text: https://secwatch.observer/filing/0001826466-24-000050.txt

## Key facts
- M&A Transactions
  NIKA PHARMACEUTICALS, INC completed an acquisition involving Nika BioTechnology, Inc. (closed 2024-04-10).
  - Action: acquisition
  - Counterparty: Nika BioTechnology, Inc.
  - Closing: 2024-04-10
  source text: Pursuant to the terms of the merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals, Inc., Nika Pharmaceuticals, Inc. has acquired the 40% stake in Nika Europe Ltd. that was owned by Nika BioTechnonoly, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145604/000182646624000050/0001826466-24-000050-index.htm
- M&A Transactions
  NIKA PHARMACEUTICALS, INC completed an acquisition involving Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology for 45,000 BGN (equivalent to around 24,683 USD).
  - Action: acquisition
  - Counterparty: Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology
  - Consideration: 45,000 BGN (equivalent to around 24,683 USD)
  source text: a dietary supplement. The technologies were purchased from Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology (“AIPFPCB”) for a total price of 45,000 BGN (equivalent to around 24,683 USD) that was paid by Dimitar Slavchev Savov who is an officer and director of Nika Pharmaceuticals, Inc. and the general manager of Nika
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145604/000182646624000050/0001826466-24-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.